{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:21:21Z","timestamp":1776896481331,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00291"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00083"],"award-info":[{"award-number":["PI19\/00083"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.yexcr.2023.113718","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T11:04:59Z","timestamp":1689591899000},"page":"113718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["BET inhibitors induce NF-\u03baB and E2F downregulation in Hodgkin and Reed\u2013Sternberg cells"],"prefix":"10.1016","volume":"430","author":[{"given":"Sara","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia G.","family":"Rita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0806","authenticated-orcid":false,"given":"Juan F.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yexcr.2023.113718_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0000000000000396","article-title":"The genetics of Hodgkin lymphoma: an overview and clinical implications","volume":"29","author":"Borchmann","year":"2017","journal-title":"Curr. Opin. Oncol."},{"issue":"5","key":"10.1016\/j.yexcr.2023.113718_bib2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cancers14051360","article-title":"The Hodgkin lymphoma immune microenvironment: turning bad news into good","volume":"14","author":"Men\u00e9ndez","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.yexcr.2023.113718_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2011.194","article-title":"Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes","volume":"26","author":"Ammerpohl","year":"2012","journal-title":"Leuk"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.yexcr.2023.113718_bib6","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.yexcr.2023.113718_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.yexcr.2023.113718_bib8","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"67","key":"10.1016\/j.yexcr.2023.113718_bib9","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22799","article-title":"Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets","volume":"8","author":"Mata","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113718_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-019-0195-7","article-title":"Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma","volume":"9","author":"Mata","year":"2019","journal-title":"Blood Cancer J."},{"issue":"7338","key":"10.1016\/j.yexcr.2023.113718_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.yexcr.2023.113718_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113718_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","article-title":"Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis","volume":"36","author":"Br\u00f6ckelmann","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminhematol.2013.01.003","article-title":"Aberrant epigenetic gene regulation in lymphoid malignancies","volume":"50","author":"Taylor","year":"2013","journal-title":"Semin. Hematol."},{"issue":"6","key":"10.1016\/j.yexcr.2023.113718_bib15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2023.113718_bib16","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"OncoTargets Ther."},{"issue":"7327","key":"10.1016\/j.yexcr.2023.113718_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113718_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-020-0218-z","article-title":"BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling","volume":"9","author":"Zhou","year":"2020","journal-title":"Oncogenesis"},{"issue":"7360","key":"10.1016\/j.yexcr.2023.113718_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Trabucco","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7327","key":"10.1016\/j.yexcr.2023.113718_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.yexcr.2023.113718_bib22","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1182\/bloodadvances.2021005948","article-title":"Triple combination of BET plus PI3K and NF-kB inhibitors exhibit synergistic activity in adult T-cell leukemia\/lymphoma","volume":"6","author":"Daenthanasanmak","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.yexcr.2023.113718_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/bj3570263","article-title":"Relationships between inhibition constants, inhibitor concentrations for 50 % inhibition and types of inhibition: new ways of analysing data","volume":"357","author":"Corte","year":"2001","journal-title":"Biochem. J."},{"issue":"15","key":"10.1016\/j.yexcr.2023.113718_bib24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.yexcr.2023.113718_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004310","article-title":"Time-course gene set analysis for longitudinal gene expression data","volume":"11","author":"Hejblum","year":"2015","journal-title":"PLoS Comput. Biol."},{"issue":"4","key":"10.1016\/j.yexcr.2023.113718_bib26","article-title":"JAK\/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells","author":"Fern\u00e1ndez","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.yexcr.2023.113718_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/genes8040115","article-title":"Role of MYC in B cell lymphomagenesis","volume":"8","author":"Korac","year":"2017","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03545-x","article-title":"The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer","volume":"20","author":"Pang","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.yexcr.2023.113718_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin. Cancer Biol."},{"issue":"15","key":"10.1016\/j.yexcr.2023.113718_bib30","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-\u03baB","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.yexcr.2023.113718_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/modpathol.3880306","article-title":"Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells","volume":"14","author":"Izban","year":"2001","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.yexcr.2023.113718_bib32","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.yexcr.2023.113718_bib33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/annonc\/mdn365","article-title":"Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma","volume":"19","author":"Mendle","year":"2008","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.yexcr.2023.113718_bib34","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2006-10-053959","article-title":"NF-\u03baB \u2013 independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs","volume":"109","author":"Kashkar","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113718_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.15252\/embr.201540121","article-title":"The second coming of epigenetic drugs","volume":"16","author":"Hunter","year":"2015","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.yexcr.2023.113718_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","article-title":"Epigenetics: a landscape takes shape","volume":"128","author":"Goldberg","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.yexcr.2023.113718_bib38","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1159\/000472407","article-title":"Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma","volume":"41","author":"Wu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.yexcr.2023.113718_bib39","first-page":"2503","article-title":"Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression","author":"Tan","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.yexcr.2023.113718_bib40","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.yexcr.2023.113718_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","article-title":"A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma","volume":"2","author":"Blum","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-36976-1","article-title":"BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas","volume":"14","author":"Moreno","year":"2023","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.yexcr.2023.113718_bib43","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Ott","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.yexcr.2023.113718_bib44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"40","key":"10.1016\/j.yexcr.2023.113718_bib45","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"31","key":"10.1016\/j.yexcr.2023.113718_bib46","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.yexcr.2023.113718_bib47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.yexcr.2023.113718_bib48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"issue":"7327","key":"10.1016\/j.yexcr.2023.113718_bib49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.yexcr.2023.113718_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111578","article-title":"The Rb\/E2F axis is a key regulator of the molecular signatures instructing the quiescent and activated adult neural stem cell state","volume":"41","author":"Fong","year":"2022","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.yexcr.2023.113718_bib51","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1084\/jem.20160719","article-title":"Rb family proteins enforce the homeostasis of quiescent hematopoietic stem cells by repressing Socs 3 expression","volume":"214","author":"Kim","year":"2017","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.yexcr.2023.113718_bib52","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.stem.2008.07.009","article-title":"Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family","volume":"3","author":"Viatour","year":"2008","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113718_bib53","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2014.930850","article-title":"Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma","volume":"56","author":"Georgiadi","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.yexcr.2023.113718_bib54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/path.1661","article-title":"Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors","volume":"204","author":"S\u00e1nchez-Beato","year":"2004","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.yexcr.2023.113718_bib55","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.yexcr.2023.113718_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.yexcr.2023.113718_bib57","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1038\/s41375-020-0816-y","article-title":"Mutational mechanisms of EZH2 inactivation in myeloid neoplasms","volume":"34","author":"Chase","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/PAS.0000000000001180","article-title":"Utility of combined EZH2, p-ERK1\/2, p-STAT, and MYC expression in the differential diagnosis of EZH2-positive Hodgkin lymphomas and related large B-cell lymphomas","volume":"43","author":"Tian","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.yexcr.2023.113718_bib59","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","article-title":"SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial","volume":"9","author":"Song","year":"2022","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.yexcr.2023.113718_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-023-01452-6","article-title":"Clinical advances in epigenetic therapies for lymphoma","volume":"15","author":"Rosenthal","year":"2023","journal-title":"Clin. Epigenet."},{"issue":"2","key":"10.1016\/j.yexcr.2023.113718_bib61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41375-022-01774-z","article-title":"Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma","volume":"37","author":"Wei","year":"2023","journal-title":"Leukemia"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482723002665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482723002665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:22:22Z","timestamp":1762147342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482723002665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0014482723002665"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2023.113718","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BET inhibitors induce NF-\u03baB and E2F downregulation in Hodgkin and Reed\u2013Sternberg cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2023.113718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113718"}}